Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.25
-0.0150-1.19%
Volume:83.64K
Turnover:103.63K
Market Cap:80.06M
PE:-3.92
High:1.26
Open:1.26
Low:1.23
Close:1.26
52wk High:3.82
52wk Low:0.7708
Shares:64.31M
Float Shares:52.11M
Volume Ratio:1.80
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3175
EPS(LYR):-0.3175
ROE:-65.70%
ROA:-30.80%
PB:0.93
PE(LYR):-3.92

Loading ...

iBio Chief Legal Officer Marc Banjak acquires common shares; $23,028 value

Reuters
·
Mar 28

iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating

TIPRANKS
·
Mar 27

iBio CFO Felipe Duran buys USD 50,000 of common shares

Reuters
·
Mar 23

iBio CEO and CSO Martin Brenner acquires USD 24,919 of common shares

Reuters
·
Mar 23

Ibio (IBIO) Receives a Buy from LifeSci Capital

TIPRANKS
·
Mar 21

Buy Rating on iBio Driven by Differentiated Activin-Targeting Antibody and Large PH-HFpEF Market Opportunity

TIPRANKS
·
Mar 19

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 18

Ibio Inc - Expects to Declare Bispecific Antibody Candidate for Ph-Hfpef in Q3 2026

THOMSON REUTERS
·
Mar 17

Ibio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (Ph-Hfpef)

THOMSON REUTERS
·
Mar 17

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

GlobeNewswire
·
Mar 17

Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile

TIPRANKS
·
Mar 10

Ibio Inc - Ibio-610 Reduced Visceral Fat by 6.7% and Total Fat Mass by 5.2% in Nhp Study

THOMSON REUTERS
·
Mar 09

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

GlobeNewswire
·
Mar 09